Redeye comments on today’s news that Annexin’s rights issue was fully subscribed.
Obducat AB (publ) (”Obducat” eller ”Bolaget”) är en ledande leverantör av litografilösning och har u...
This morning, it was announced that Sebastian Larsson will take over the CEO role.
Redeye comments on Cantargia's two new abstracts from the AACR meeting 2025, the first about nadunol...
Redeye comments on TH1NG’s Q4 report, in which revenues slightly exceeded expectations, but a signif...
Irisity AB (”Irisity” or ”the Company”) published its Q4 report for 2024 on the 25th of March 2025.
A demanding comparable quarter, temporary negative quarterly deviations, and weekly phasing are tran...
Redeye updates its estimates ahead of Waystream’s Q1 report, due 24 April.
Redeye gives an initial take on Eisai’s simulated revenues for its FY2027, which is lower than we ha...
Redeye comments on Arise’s 125MW BESS divestment through its Finish subsidiary Pohjan Voima, which A...
Redeye provides some additional comments and makes positive valuation changes following GomSpace's c...
Powercell today announced its first order for a methanol to power system from a European shipyard.
Pharma Equity Group (“PEG” or “the Company”) has recently refined the Company’s execution strategy, ...
EQL Pharma tillverkar läkemedel där patenten gått ut, så kallad generika.
In the Asian region Vitrolife faces a challenging period.
Redeye initiates coverage of Momentum Group, a niche serial acquirer of high-quality industrial SMEs...
EMB Mission Bound (”EMB” eller ”Bolaget”), f.d. Embark Group, har publicerat bolagets delårsrapport ...
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 21 mars 2025 att Koncernens nyligen...
Acquiring consulting company BlakYaks at 10.7x EV/EBITA Seems to be a good growing and highly profit...
PW: Q1 EBIT below Q4 of SEK -28m Large negative effects from wood, FX and CTMP Higher wood costs and...
